Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Seres Therapeutics ( (MCRB) ) has issued an update.
On September 23, 2025, Seres Therapeutics announced a reduction in operating costs to extend its cash runway, including a 25% workforce reduction effective from August 2025. This move aims to advance strategic priorities, with expected severance-related cash charges of $1.0 to $1.4 million to be paid in the fourth quarter of 2025, potentially extending the cash runway into the second quarter of 2026.
The most recent analyst rating on (MCRB) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Seres Therapeutics stock, see the MCRB Stock Forecast page.
Spark’s Take on MCRB Stock
According to Spark, TipRanks’ AI Analyst, MCRB is a Neutral.
Seres Therapeutics’ overall score reflects significant financial challenges with unstable revenue, high debt, and negative cash flows. Technical indicators suggest bearish momentum, while valuation is affected by negative earnings. The earnings call provided some optimism with SER-155 progress and financial improvements, but uncertainties remain. Overall, the stock score indicates caution due to financial instability and bearish technical trends.
To see Spark’s full report on MCRB stock, click here.
More about Seres Therapeutics
Seres Therapeutics, Inc. operates in the biotechnology industry, focusing on developing microbiome therapeutics to treat diseases and improve patient health.
Average Trading Volume: 176,691
Technical Sentiment Signal: Hold
Current Market Cap: $179.5M
For a thorough assessment of MCRB stock, go to TipRanks’ Stock Analysis page.